rosiglitazone / Generic mfg. - LARVOL DELTA

Role of ferroptosis in aGVHD-induced liver tissue damage: Mediation by Acsl4-regulated PUFA-pls (ASH 2025) - "Collectively, our findings highlight the importance of ferroptosis in the pathogenesis ofaGVHD-induced liver tissue damage, which is regulated by the Acsl4 mediated PUFA-PLs accumulation.Modulation of ferroptosis during transplantation may be an effective approach for preventing or treatingacute liver GVHD. More importantly, we provide a scientific rationale for ruxolitinib combined withrosiglitazone in patients with SR-aGVHD involved liver."

Acute Graft versus Host Disease • Alopecia • Bone Marrow Transplantation • Graft versus Host Disease • Hepatology • Immunology • Inflammation • Liver Failure • Metabolic Disorders • ACSL4 • GPX4 • PACERR • PTGS2

Bone marrow adipocytes fuel hematopoietic regeneration via fatty acid release (ASH 2025) - "Pharmacologic modulation of bone marrowadipocytes using rosiglitazone (which increases adipocytes) and bisphenol A diglycidyl ether (BADGE,which decreases adipocytes) did not affect steady-state hematopoiesis or HSC frequency and function.However, these treatments significantly impacted hematopoietic regeneration after bone marrowtransplantation, with rosiglitazone promoting and BADGE inhibiting recovery...Conditional deletion of these genes in HSCs did not affect steady-state hematopoiesis butsignificantly impaired regeneration, highlighting the critical role of FA oxidation in HSCs during stress.To identify the source of FA, we generated Lepr-CreER; Pnpla2fl/fl mice, in which Pnpla2 (encodingadipose triglyceride lipase, ATGL) was conditionally deleted in LEPR+ cells and their adipocyte progeny.Following tamoxifen induction, these mice exhibited normal steady-state hematopoiesis but impairedregeneration, with reduced FA levels in HSPCs...Next, we developed a dual..."

Bone Marrow Transplantation • Hematological Disorders • CD36 • LEPR • SCARB1

Multi-omics integration deciphers immune-metabolic heterogeneity in CRC: A prognostic model and therapeutic strategies targeting ANGPTL4/FABP4/RBP7. (PubMed, Comput Biol Med) - "This multi-omics study integrates multi-omics data to elucidate the immune-metabolic heterogeneity in CRC, establishing a precise prognostic model and providing bioinformatic evidence for key roles of ANGPTL4, FABP4, and RBP7 in the tumor microenvironment, thereby suggesting novel strategies to overcome immunotherapy resistance."

Heterogeneity • IO biomarker • Journal • Colorectal Cancer • Oncology • Solid Tumor • ANGPTL4 • APOD • BST2 • CCL2 • CCL22 • CD8 • CX3CL1 • FABP4 • MIR21 • NOS2 • PD-L1 • RBP7 • TGFB3

GB5, a synergistic phytotherapy for type 2 diabetes mellitus management: an integrated polyherbal approach from phytochemical profiling to network pharmacology. (PubMed, BMC Complement Med Ther) - "GB5's multi-targeted efficacy against hyperglycaemia, oxidative stress, and adipocyte dysfunction positions it as a promising complementary therapy for T2DM, meriting further in vivo evaluation."

Journal • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • PPARG • PTPN1

Investigating the Role of Peroxisomes in Regulating Breast Cancer Stem Cell Mechanisms. (PubMed, Int J Mol Sci) - "To independently validate our observations, MCF-7 cells were also treated with Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist that enhances peroxisome levels...This decline in stemness was accompanied by an approximately one-and-a-half-fold increase in ROS levels and a five-fold increase in lipid peroxidation, reflecting increased mitochondrial lipid peroxidation and ferroptosis. Continued research is, however, essential to further validate these findings and to elucidate the underlying mechanisms."

Journal • Breast Cancer • Oncology • Solid Tumor

Simultaneous targeting of multiple etiological using a nanosized strategy for psoriasis management. (PubMed, Mater Today Bio) - "In this study, we developed a bilirubin-conjugated hyaluronic acid-assembled, lapatinib/rosiglitazone-coloaded nanoparticle (LR@HBn) to target both peroxisome proliferator-activated receptor γ (PPARγ) and epidermal growth factor receptor (EGFR) as well as intervene nuclear factor kappa B (NF-κB) signaling to effectively alleviate the progression of psoriasis by suppressing inflammatory microenvironment, preventing abnormal cellular growth, scavenging reactive oxygen species (ROS), and inhibiting interleukin-17A secretion. In vitro and in vivo experiments revealed excellent antioxidative, anti-inflammatory, anti-proliferative features and safety of LR@HBn, with resultant attenuation of psoriatic disease progression and suppression of recurrence. Taken collectively, these results point to LR@HBn as a promising and advanced strategy for treating psoriasis by administering topically."

Journal • Dermatology • Immunology • Inflammation • Psoriasis • EGFR • IL17A • PPARG

Thermogenic Differentiation of Human Adipocyte Precursors in Culture: A Systematic Review. (PubMed, Cells) - "Most studies relied on classical adipogenic inducers, including isomethylbutylxanthine, dexamethasone, and insulin, with additional use of triiodothyronine, rosiglitazone, or indomethacin. A key limitation remains the predominant reliance on gene expression as the primary outcome, with few studies assessing mitochondrial respiration or broader metabolic functions. Moving forward, the development and adoption of standardized, functionally validated protocols will be critical to fully realize the potential of human in vitro thermogenic adipocyte models in metabolic research."

Journal • Review • Metabolic Disorders

Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes. (PubMed, Front Pharmacol) - "Functionally, in 3T3-L1 adipocytes, thiamine induced adipogenesis and PPARγ-response element binding with a potency analogous to rosiglitazone, suggesting direct agonistic activity. Corroborating these mechanistic insights at the clinical level, a new meta-analysis of randomized controlled trials demonstrates that high-dose benfotiamine, a synthetic thiamine derivative, significantly improves neuropathic and vascular outcomes in T2D patients. While the contribution of thiamine's established antioxidant effects to these clinical benefits cannot be ruled out, the synergy of computational, cellular, and human evidence provides a compelling foundation for our hypothesis. This study suggests that thiamine could act as a PPARγ ligand and serve as a safer treatment option for metabolic disorders, which needs to be tested in vivo."

Journal • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • PPARG

NOC4L coordinates neuronal and pharyngeal arch development by regulating ribosome biogenesis. (PubMed, J Mol Cell Biol) - "Pharmacological PPARγ activation via rosiglitazone partially rescued craniofacial malformations, ameliorated neurodevelopmental defects, and prolonged mutant life span. Although inhibition of the p53 pathway can partially rescue the phenotype, the p53 pathway and metabolic pathways are likely independent contributing factors. Our study reveals the molecular basis of developmental defects in noc4l mutants through impaired ribosome assembly and demonstrates the therapeutic potential of metabolic interventions for ribosomopathies."

Journal • Genetic Disorders • PPARG

Mechanistic insights into PPARγ's role in suppressing collagen-driven platelet activation. (PubMed, Life Sci) - "These findings identify PPARγ as a regulator of early platelet activation by targeting both Lyn- and Fyn-dependent proximal GPVI signaling and highlight PPARγ ligands as potential dual-purpose therapeutics with antithrombotic benefits alongside their metabolic actions."

Journal • LYN • PLCG2 • PPARG • SYK • VAV1

Interaction Between Microglial Lipid Droplet Metabolism and Immune Polarisation After Stroke: Mechanisms and Therapeutic Prospects. (PubMed, Cell Mol Neurobiol) - "The development of LD-related biomarkers (such as near-infrared imaging), the repurpose of peroxisome proliferator-activated receptor γ agonists (rosiglitazone) and HDAC inhibitors (volinostat), as well as the design of novel drugs (such as Triggering Receptor Expressed on Myeloid Cells 2 agonists and perilipin 2 small interfering RNA) are expected to improve stroke outcomes by transforming metabolic homeostasis and immune balance. Multi-omics technology and intelligent delivery system should be combined to overcome the limitations of the blood-brain barrier, promote the clinical transformation of the "metabolism-immunity" collaborative intervention strategy, and provide a new paradigm for precision treatment of stroke."

Journal • Review • Cardiovascular • CNS Disorders • Inflammation • PLIN2

Rosiglitazone Mitigates Valproic Acid-Induced Neurotoxicity in Zebrafish Larvae via Activation of the PPAR Pathway. (PubMed, J Appl Toxicol) - "Transcriptomic analysis and qRT-PCR revealed that VPA downregulated PPAR pathway genes (ppara, pparg, pck1, and fabp1), while RGZ cotreatment partially restored locomotor activity, normalized neurotransmitter levels, and rescued PPAR pathway gene expression. These findings demonstrate that RGZ mitigates VPA-induced neurotoxicity by activating PPAR signaling, restoring metabolic balance, and improving motor function, suggesting PPAR agonists as potential therapeutic agents for VPA-induced neurotoxicity and ASD-related deficits."

Journal • Autism Spectrum Disorder • CNS Disorders • Epilepsy • Genetic Disorders • Mental Retardation • Psychiatry • FABP1 • PPARA

A deep representation learning algorithm on drug-target interaction to screen novel drug candidates for Alzheimer's disease. (PubMed, Artif Intell Med) - "Our results identified that several drugs could be promising for AD treatment, including human C1-esterase inhibitor, quetiapine, dasatinib, miconazole, aniracetam, chlorpromazine, hypericin, entrectinib, torcetrapib, bosutinib, sunitinib, aniracetam, rosiglitazone, tarenflurbil, milrinone, and MITO-4509. Results from this study also provided insights for understanding the molecular mechanisms underlying AD. As a systematic and versatile method, our approach can also be applied to identify efficacious therapies for other complex diseases."

Journal • Alzheimer's Disease • CNS Disorders

Modulation of PM20D1 expression by rosiglitazone confers neuroprotection in tramadol-induced Parkinsonian rats. (PubMed, Toxicol Rep) - "Parkinson's disease (PD) is a progressive neurodegenerative disorder with no available disease‑modifying therapy, and tramadol misuse has been increasingly associated with PD‑like neurotoxicity through oxidative stress, mitochondrial dysfunction, and apoptosis. The low-dose RSG plus levodopa-carbidopa combination achieved maximal behavioral recovery and dopamine restoration (1023.0 ± 248.0 pg/mL) compared to the tramadol-only group. These findings provide the first evidence that RSG confers neuroprotection against tramadol-induced Parkinsonism through PPARγ-mediated modulation of PM20D1 gene expression, highlighting a novel translational therapeutic axis with potential disease-modifying implications for PD."

IO biomarker • Journal • Preclinical • CNS Disorders • Metabolic Disorders • Movement Disorders • Parkinson's Disease • BCL2 • CASP3 • CASP9

Repurposed Drugs for Heterotopic Ossification Management: Revitalizing Therapeutic Strategies. (PubMed, Pharmaceuticals (Basel)) - " We performed docking experiments between peroxisome proliferator-activated receptor-γ and bone metabolism-affecting drugs, namely, thiazolidinediones (rosiglitazone, pioglitazone), indomethacin, and dexamethasone, to test tritherapy antiosteoblastogenic effect. These results were consistent with bone turnover modification observed in a congenital HO patient. This concordance underscores tritherapy potential for rapid and safe translation to prevent HO."

Journal • FABP4 • SPP1

Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review. (PubMed, J Pers Med) - " We systematically searched PubMed, Scopus, and Web of Science for studies published from the earliest available records to 18 August 2025 using the following Boolean search terms: "miRNA AND gliclazide", "miRNA AND glibenclamide", "miRNA AND gliquidone", "miRNA AND glimepiride", "mirRNA AND metformin", "miRNA AND pioglitazone", "miRNA AND rosiglitazone", "miRNA AND sitagliptin", "miRNA AND vildagliptin", "miRNA AND alogliptin", "miRNA and saxagliptin", "miRNA AND linagliptin", "miRNA AND liraglutide", "miRNA and dulaglutide", "miRNA AND semaglutide", "miRNA AND tirzepatide", "miRNA AND lixisenatide", "miRNA AND empagliflozin", "miRNA AND dapagliflozin", miRNA AND insulin glargine", "miRNA AND insulin detemir", "miRNA AND insulin degludec", "miRNA AND..."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Peroxisome proliferator-activated receptors as novel targets of small cell lung cancer circulating tumor cells. (PubMed, Neoplasma) - "Cytotoxicity varied by compound, while the PPARγ agonist pioglitazone and the PPARα agonist fenofibrate were preferentially active in CTC lines, DG172 hydrochloride was selective for pleural effusion-derived lines, while rosiglitazone maleate, cloxiquine, and agrimol B showed no selectivity. These findings support PPARs as clinically relevant targets in SCLC, with PPAR-directed agents showing cytotoxic effects comparable to those reported in other malignancies. Such agents may aid SCLC treatment and help delineate biological differences between CTCs and resident tumor cells."

Circulating tumor cells • Journal • Lung Cancer • Oncology • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • BCL2 • BCL2L1 • CASP3 • CASP9 • CFLAR • CTCs • CXCR4 • ICAM1 • PPARA

Optimizing adipogenic cocktail composition to enhance beige adipogenesis and evaluate thermogenic potential in primary mouse subcutaneous fat cell cultures. (PubMed, Int J Obes (Lond)) - "These findings underscore the importance of optimizing adipogenic cocktails, as they significantly influence experimental outcomes. This study offers valuable guidance for selecting effective combinations of adipogenic inducers tailored to specific research objectives and relevant in vitro models of beige adipose biology."

Journal • Preclinical

Effect of Oral Hypoglycaemic Agents on Carotid Artery Intima-Media Thickness in Patients With Cardiovascular Disease and/or Diabetes-A Systematic Review. (PubMed, Endocrinol Diabetes Metab) - "The study suggests that prolonged use of Pioglitazone, Repaglinide and Alogliptin may significantly slow CIMT progression, improving cardiovascular risk management in patients with diabetes and/or cardiovascular disease. Further research is needed to understand the benefits and optimise oral hypoglycaemic treatment strategies for these patients."

Journal • Review • Atherosclerosis • Cardiovascular • Diabetes • Hypoglycemia • Inflammation • Metabolic Disorders • Type 1 Diabetes Mellitus

Rational in silico design of PPARγ agonists for type 2 diabetes: an integrated study using pharmacophore modeling, 3D-QSAR, molecular docking, MD simulations, DFT, and toxicity prediction. (PubMed, Mol Divers) - "These compounds showed superior docking scores (- 10.919 to - 10.386 kcal/mol) and MM-GBSA energies (- 85.9 to - 63.96 kcal/mol) compared to the internal ligand SR145 (- 10.351 kcal/mol, - 85.63 kcal/mol) and standard drugs; rosiglitazone (- 7.272 kcal/mol, - 48.14 kcal/mol) and pioglitazone (- 7.033 kcal/mol, - 47.21 kcal/mol). Among the four identified hits, CHEMBL1825121 and CHEMBL4569907 were identified as the top candidates, displaying strong binding affinity, high structural stability and favorable pharmacokinetic properties. While experimental validation remains essential, these findings provide a rational strategy for the development of next-generation PPARγ modulators for T2DM."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

PPARγ ligands activate the ion channel TRPA1. (PubMed, Eur J Pharmacol) - "Troglitazone, rosiglitazone, nTZDpa, and the PPARγ antagonist GW9662 evoked concentration-dependent Ca2+-influx responses in TRPA1 expressing, but not untransfected Chinese hamster ovary (CHO)cells...Responses were abolished by the TRPA1 antagonist A967079 and were absent in DRG neurons from Trpa1-/- mice...Intraplantar injections of troglitazone evoked pain-responses in wild-type mice, but not in Trpa1-/- mice. Our molecular docking studies indicate that nTZDpa and troglitazone bind to overlapping sites in a hydrophobic pocket in the pre-S1 helix These observations demonstrate that multiple PPARγ ligands stimulate TRPA1 and that nTZDpa may be a useful tool for investigations of TRPA1."

Journal • Pain • PPARG • TRPA1

Hollow Polydopamine-Based Renal Tubule-Targeted Nanoplatform for Ferroptosis Inhibition and Fibrosis Amelioration (KIDNEY WEEK 2025) - "Previous researches have indicated that ferroptosis plays a crucial role in driving renal RIF, and can be inhibited by ferroptosis inhibitors, such as rosiglitazone (Rosi)...Conclusion By integrating targeted Rosi delivery with multimodal mechanisms—ferroptosis inhibition, mitochondrial protection, and inflammation modulation—Rosi@HPDA-PEG-K3 NPs significantly ameliorated RIF progression with favorable biosafety. Our study advances mechanistic insights into ferroptosis regulation in renal fibrosis and establishes a nanotherapeutic platform with precise targeting, controlled release, and multifunctional efficacy, highlighting its scientific rigor and clinical translational potential."

Chronic Kidney Disease • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease • ACSL4 • TGFB1

Risks and Harms to Physicians Reporting Hematologic Adverse Drug Reactions (ADRs) to Health Authorities (ASH 2024) - "ADR findings resulted in drug removal (n = 7; Vioxx, Avandia, Bextra, Celebrex, Trasylol, Phenyl propanolamine, Hydroxy-ethyl starch), revised indications (n = 2) (Procrit, Aranesp 2007, 2008, 2010)) or 10-year delay in FDA-approval (n = 1) (Fereprox)...Pharmaceutical companies paid $600,000 (Fereprox) to $5.8 billion (Vioxx) in fines and settlements.Discussion : Twelve physicians experienced severe threats and/or harms after reporting hematologic-associated ADRs to Health Authorities and/or in major publications. We suggest physicians not sign secrecy agreements that might jeopardize public safety (as currently established by almost all US medical universities) and should partner with independent drug safety monitoring boards (DSMBs) on ADR evaluations to monitor safety concerns of drugs and medical devices."

Adverse drug reaction • Hematological Disorders • Oncology • Solid Tumor

Utilization and Expenditures of Medications Withdrawn From Markets Due to Safety Concerns in China (ISPOR-EU 2025) - "On average, 4.93% of total medication expenditures were attributed to these medications, with gangliosides, rosiglitazone, and pioglitazone accounting for the highest costs. Despite safety concerns, withdrawn medications remain in use and contribute notably to medication spending in China. Older adults, males, and individuals with certain insurance benefits are more likely to use them. Strengthened regulatory oversight and enhanced pharmacoepidemiologic monitoring are essential to ensure medication safety and optimize healthcare resource use."

Clinical

Retinoic Acid and Vitamin D Co-Supplementation Reduces Obesity and Enhances Thermoregulation (OBESITY WEEK 2025) - "HFD + Rosiglitazone (R, 10 mg/Kg), 4... RA+VD supplementation has the potential to provide enhanced metabolic benefits by reducing adiposity and may partially preserve thermoregulatory capacity under cold stress, compared to single treatments."

Genetic Disorders • Obesity